Stocks · News reference

Barclays Maintains Overweight on Kanzhun, Raises Price Target to $20

Aug 27, 2026, 3:21 PMBenzinga Newsdesk

Barclays analyst Jiong Shao maintains Kanzhun (NASDAQ:BZ) with a Overweight and raises the price target from $19 to $20.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 26, 2026, 2:16 PMAvi Kapoor
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.
Read original at benzinga
ACHC AEO ALHC ANF BZ
BenzingaAug 25, 2026, 4:46 PMBenzinga Newsdesk
Kanzhun shares are trading higher after the company reported better-than-expected Q2 EPS results.
Read original at benzinga
BZ
BenzingaAug 25, 2026, 1:31 PMBenzinga Insights
Transcript: Kanzhun Q2 2026 Earnings Conference Call
Kanzhun (NASDAQ:BZ) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and
Read original at benzinga
BZ